{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:04:22Z","timestamp":1791875062592,"version":"4.3.4"},"reference-count":129,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002373"],"award-info":[{"award-number":["UL1TR002373"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR002374"],"award-info":[{"award-number":["KL2TR002374"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Ultrasound, CT and MRI"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1053\/j.sult.2020.08.011","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T03:35:20Z","timestamp":1598672120000},"page":"572-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions"],"prefix":"10.1053","volume":"41","author":[{"given":"Paul A.","family":"Rowley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey A.","family":"Samsonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobey J.","family":"Betthauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Pirasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sterling C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Eisenmenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.sult.2020.08.011_bib0001","unstructured":"Dementia: Fact sheet N\u00b0362. World Health Organization (WHO)2019[Available from:https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/dementia."},{"key":"10.1053\/j.sult.2020.08.011_bib0002","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/brain\/aww230","article-title":"Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration","volume":"140","author":"Goedert","year":"2017","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0003","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0004","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11604-019-00867-7","article-title":"Neuroimaging of Alzheimer's disease: Focus on amyloid and tau PET","volume":"37","author":"Matsuda","year":"2019","journal-title":"Jpn J Radiol"},{"key":"10.1053\/j.sult.2020.08.011_bib0005","first-page":"e12007","article-title":"Amyloid duration is associated with preclinical cognitive decline and tau PET","volume":"12","author":"Koscik","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1053\/j.sult.2020.08.011_bib0006","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/brain\/awz378","article-title":"Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age","volume":"143","author":"Betthauser","year":"2020","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0007","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.sult.2020.08.011_bib0008","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.sult.2020.08.011_bib0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.sult.2020.08.011_bib0011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9758\/cpn.2017.15.1.1","article-title":"Mechanisms of Alzheimer's Disease pathogenesis and prevention: The brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors","volume":"15","author":"Kocahan","year":"2017","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1053\/j.sult.2020.08.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006262","article-title":"Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease","volume":"2","author":"Masters","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0014","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.1053\/j.sult.2020.08.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005777","article-title":"Synapses and Alzheimer's disease","volume":"4","author":"Sheng","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1053\/j.sult.2020.08.011_bib0016","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","article-title":"The amyloid hypothesis for Alzheimer's disease: a critical reappraisal","volume":"110","author":"Hardy","year":"2009","journal-title":"J Neurochem"},{"key":"10.1053\/j.sult.2020.08.011_bib0017","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1053\/j.sult.2020.08.011_bib0018","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","article-title":"Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective","volume":"120","author":"Tanzi","year":"2005","journal-title":"Cell"},{"key":"10.1053\/j.sult.2020.08.011_bib0019","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"10.1053\/j.sult.2020.08.011_bib0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awm336","article-title":"11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment","volume":"131","author":"Jack","year":"2008","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0021","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging beta-amyloid burden in aging and dementia","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0022","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/pcn.12326","volume":"69","author":"Omachi","year":"2015","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1053\/j.sult.2020.08.011_bib0023","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2967\/jnumed.106.037762","article-title":"Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease","volume":"48","author":"Ng","year":"2007","journal-title":"J Nucl Ned"},{"key":"10.1053\/j.sult.2020.08.011_bib0024","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","article-title":"Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study","volume":"68","author":"Edison","year":"2007","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0025","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","article-title":"Impact of molecular imaging on the diagnostic process in a memory clinic","volume":"9","author":"Ossenkoppele","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.sult.2020.08.011_bib0026","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","article-title":"Diagnostic accuracy of (18)F amyloid PET radiotracers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis","volume":"43","author":"Morris","year":"2016","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"10.1053\/j.sult.2020.08.011_bib0027","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archneur.55.3.326","article-title":"Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype","volume":"55","author":"Berg","year":"1998","journal-title":"Arch Neurol"},{"issue":"Pt 6","key":"10.1053\/j.sult.2020.08.011_bib0028","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0029","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/archneur.64.3.431","article-title":"Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report","volume":"64","author":"Bacskai","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.arr.2016.01.005","article-title":"Amyloid imaging: Past, present and future perspectives","volume":"30","author":"Villemagne","year":"2016","journal-title":"Ageing Res Rev"},{"key":"10.1053\/j.sult.2020.08.011_bib0031","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00259-013-2478-8","article-title":"[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment","volume":"40","author":"Bruck","year":"2013","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"10.1053\/j.sult.2020.08.011_bib0032","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1002\/hbm.24782","article-title":"Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment","volume":"40","author":"Chandra","year":"2019","journal-title":"Hum Brain Mapp"},{"key":"10.1053\/j.sult.2020.08.011_bib0033","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","article-title":"Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment","volume":"39","author":"Camus","year":"2012","journal-title":"Eur J Nuc Med Mol Imaging"},{"issue":"5 Suppl","key":"10.1053\/j.sult.2020.08.011_bib0034","first-page":"S72","article-title":"Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.sult.2020.08.011_bib0035","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s12149-015-0978-2","article-title":"Imaging characteristics and safety of florbetapir ((1)(8)F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease","volume":"29","author":"Namiki","year":"2015","journal-title":"Ann Nuc Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0036","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)","volume":"51","author":"Wong","year":"2010","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0037","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1212\/WNL.0b013e3182661f74","article-title":"Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study","volume":"79","author":"Doraiswamy","year":"2012","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0038","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/03007995.2016.1277197","article-title":"Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir","volume":"33","author":"Hornberger","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.sult.2020.08.011_bib0039","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","article-title":"Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias","volume":"52","author":"Villemagne","year":"2011","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","article-title":"[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease","volume":"41","author":"Hatashita","year":"2014","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"10.1053\/j.sult.2020.08.011_bib0041","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","article-title":"Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease","volume":"50","author":"Nelissen","year":"2009","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0042","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nicl.2017.08.011","article-title":"Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals","volume":"16","author":"Lowe","year":"2017","journal-title":"NeuroImage Clin"},{"issue":"Pt 7","key":"10.1053\/j.sult.2020.08.011_bib0043","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/brain\/awv112","article-title":"Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation","volume":"138","author":"Villeneuve","year":"2015","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0044","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00259-019-04297-5","article-title":"Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis","volume":"46","author":"Leuzy","year":"2019","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"10.1053\/j.sult.2020.08.011_bib0045","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0046","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/00005072-199812000-00009","article-title":"Neuropathological and neuropsychological changes in \"normal\" aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals","volume":"5","author":"Hulette","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0047","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","article-title":"[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease","volume":"67","author":"Mintun","year":"2006","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0048","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann Neurol"},{"issue":"Pt 11","key":"10.1053\/j.sult.2020.08.011_bib0049","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","article-title":"Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease","volume":"130","author":"Pike","year":"2007","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0050","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch Neurol"},{"issue":"Pt 5","key":"10.1053\/j.sult.2020.08.011_bib0051","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awn320","article-title":"Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects","volume":"132","author":"Mormino","year":"2009","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0052","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1053\/j.sult.2020.08.011_bib0053","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1073\/pnas.0914141107","article-title":"Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's","volume":"107","author":"Mosconi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.sult.2020.08.011_bib0054","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.sult.2020.08.011_bib0055","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","article-title":"ApoE and Abeta in Alzheimer's disease: accidental encounters or partners?","volume":"81","author":"Kanekiyo","year":"2014","journal-title":"Neuron"},{"key":"10.1053\/j.sult.2020.08.011_bib0056","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jama.2019.1998","article-title":"Amyloid PET and changes in clinical management for patients with cognitive impairment","volume":"321","author":"Jack","year":"2019","journal-title":"JAMA"},{"key":"10.1053\/j.sult.2020.08.011_bib0057","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.sult.2020.08.011_bib0058","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1053\/j.sult.2020.08.011_bib0059","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40035-017-0076-6","article-title":"Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: Current and emerging concepts","volume":"6","author":"Saeed","year":"2017","journal-title":"Transl Neurodegener"},{"key":"10.1053\/j.sult.2020.08.011_bib0060","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41586-019-1026-5","article-title":"Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules","volume":"568","author":"Falcon","year":"2019","journal-title":"Nature"},{"key":"10.1053\/j.sult.2020.08.011_bib0061","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.pmbts.2019.07.007","article-title":"AD molecular: Imaging tau aggregates with positron emissions tomography","volume":"165","author":"Betthauser","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1053\/j.sult.2020.08.011_bib0062","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","article-title":"Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease","volume":"10","author":"Shoghi-Jadid","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1053\/j.sult.2020.08.011_bib0063","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"10.1053\/j.sult.2020.08.011_bib0064","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.nucmedbio.2015.08.006","article-title":"Identification of a major radiometabolite of [11C]PBB3","volume":"42","author":"Hashimoto","year":"2015","journal-title":"Nuc Med Biol"},{"key":"10.1053\/j.sult.2020.08.011_bib0065","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2967\/jnumed.112.117341","article-title":"Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease","volume":"54","author":"Okamura","year":"2013","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0066","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2967\/jnumed.115.164848","article-title":"18F-THK5351: A novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer Disease","volume":"57","author":"Harada","year":"2016","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0067","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","article-title":"Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain","volume":"9","author":"Ng","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1053\/j.sult.2020.08.011_bib0068","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography radiotracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marquie","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0069","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","article-title":"Characterization of tau positron emission tomography radiotracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias","volume":"12","author":"Sander","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.sult.2020.08.011_bib0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1053\/j.sult.2020.08.011_bib0071","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40478-017-0482-0","article-title":"Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case","volume":"5","author":"Marquie","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1053\/j.sult.2020.08.011_bib0072","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.2967\/jnumed.118.214437","article-title":"Evaluation of (18)F-RO-948 PET for quantitative assessment of tau accumulation in the human brain","volume":"59","author":"Kuwabara","year":"2018","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0073","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2967\/jnumed.117.196741","article-title":"Preclinical evaluation of (18)F-RO6958948, (11)C-RO6931643, and (11)C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer Disease","volume":"59","author":"Honer","year":"2018","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0074","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","article-title":"Preclinical characterization of 18F-MK-6240, a promising PET radiotracer for in vivo quantification of human neurofibrillary tangles","volume":"57","author":"Hostetler","year":"2016","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0075","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","article-title":"In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240","volume":"10","author":"Pascoal","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1053\/j.sult.2020.08.011_bib0076","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2967\/jnumed.118.209650","article-title":"In vivo characterization and quantification of neurofibrillary tau PET Radioligand (18)F-MK-6240 in humans from Alzheimer disease dementia to young controls","volume":"60","author":"Betthauser","year":"2019","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0077","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2967\/jnumed.118.208215","article-title":"Brain imaging of alzheimer dementia patients and elderly controls with (18)F-MK-6240, a PET radiotracer targeting neurofibrillary tangles","volume":"60","author":"Lohith","year":"2019","journal-title":"J Nuclear Med"},{"key":"10.1053\/j.sult.2020.08.011_bib0078","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","article-title":"[(18)F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease","volume":"46","author":"Sanabria Bohorquez","year":"2019","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"10.1053\/j.sult.2020.08.011_bib0079","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","article-title":"Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm","volume":"43","author":"Chiotis","year":"2016","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"10.1053\/j.sult.2020.08.011_bib0080","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/mp.2017.108","article-title":"Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia","volume":"23","author":"Chiotis","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1053\/j.sult.2020.08.011_bib0081","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","article-title":"Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET radiotracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies","volume":"46","author":"Kroth","year":"2019","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"10.1053\/j.sult.2020.08.011_bib0082","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.24711","article-title":"In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum","volume":"80","author":"Cho","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0083","first-page":"748","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition","volume":"140","author":"Pontecorvo","year":"2017","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0084","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","article-title":"Tau PET in Alzheimer disease and mild cognitive impairment","volume":"87","author":"Cho","year":"2016","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0085","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0086","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13195-018-0403-x","article-title":"Greater tau load and reduced cortical thickness in APOE epsilon4-negative Alzheimer's disease: A cohort study","volume":"10","author":"Mattsson","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1053\/j.sult.2020.08.011_bib0087","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/WCO.0000000000000502","article-title":"Update on tauopathies","volume":"30","author":"Lebouvier","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0088","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0089","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Move Disord"},{"key":"10.1053\/j.sult.2020.08.011_bib0090","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/S0002-9440(10)61154-6","article-title":"Signature tau neuropathology in gray and white matter of corticobasal degeneration","volume":"160","author":"Forman","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1053\/j.sult.2020.08.011_bib0091","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1212\/WNL.0000000000003375","article-title":"In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET","volume":"87","author":"Kikuchi","year":"2016","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0092","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1212\/WNL.0000000000004264","article-title":"In vivo retention of (18)F-AV-1451 in corticobasal syndrome","volume":"89","author":"Smith","year":"2017","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0093","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.0000000000004364","article-title":"(18)F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome","volume":"89","author":"Cho","year":"2017","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0094","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.25060","article-title":"(18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study","volume":"82","author":"Schonhaut","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0095","first-page":"781","article-title":"18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy","volume":"140","author":"Passamonti","year":"2017","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0096","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.26844","article-title":"Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy","volume":"32","author":"Cho","year":"2017","journal-title":"Move Disord"},{"key":"10.1053\/j.sult.2020.08.011_bib0097","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/mds.26813","article-title":"Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy","volume":"32","author":"Smith","year":"2017","journal-title":"Move Disord"},{"key":"10.1053\/j.sult.2020.08.011_bib0098","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mds.26727","article-title":"Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy","volume":"32","author":"Hammes","year":"2017","journal-title":"Move Disord"},{"key":"10.1053\/j.sult.2020.08.011_bib0099","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fnagi.2017.00440","article-title":"[(18)F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy","volume":"9","author":"Brendel","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1053\/j.sult.2020.08.011_bib0100","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00259-018-4104-2","article-title":"Disease-related patterns of in vivo pathology in Corticobasal syndrome","volume":"45","author":"Niccolini","year":"2018","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"10.1053\/j.sult.2020.08.011_bib0101","doi-asserted-by":"crossref","unstructured":"Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. 2003;18:1018-26.","DOI":"10.1002\/mds.10488"},{"key":"10.1053\/j.sult.2020.08.011_bib0102","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1177\/0271678X16683695","article-title":"Positron emission tomography imaging of tau pathology in progressive supranuclear palsy","volume":"37","author":"Coakeley","year":"2017","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1053\/j.sult.2020.08.011_bib0103","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1640-3","article-title":"Multimodal evaluation demonstrates in vivo (18)F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration","volume":"132","author":"McMillan","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1053\/j.sult.2020.08.011_bib0104","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mds.26834","article-title":"[(18) F]AV-1451 tau positron emission tomography in progressive supranuclear palsy","volume":"32","author":"Whitwell","year":"2017","journal-title":"Move Disord"},{"issue":"Pt 1","key":"10.1053\/j.sult.2020.08.011_bib0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/brain\/aws307","article-title":"The spectrum of disease in chronic traumatic encephalopathy","volume":"136","author":"McKee","year":"2013","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0106","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bpa.12248","article-title":"The neuropathology of chronic traumatic encephalopathy","volume":"25","author":"McKee","year":"2015","journal-title":"Brain Pathol"},{"key":"10.1053\/j.sult.2020.08.011_bib0107","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/tp.2014.91","article-title":"Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: Studies of a retired NFL player and of a man with FTD and a severe head injury","volume":"4","author":"Mitsis","year":"2014","journal-title":"Transl Psychiatry"},{"key":"10.1053\/j.sult.2020.08.011_bib0108","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1038\/tp.2016.175","article-title":"Cerebral [(18) F]T807\/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy","volume":"6","author":"Dickstein","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1053\/j.sult.2020.08.011_bib0109","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00401-008-0347-5","article-title":"Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease","volume":"115","author":"Jellinger","year":"2008","journal-title":"Acta Neuropatho"},{"key":"10.1053\/j.sult.2020.08.011_bib0110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s007020200027","article-title":"Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease","volume":"109","author":"Jellinger","year":"2002","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1053\/j.sult.2020.08.011_bib0111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0006-8993(90)90891-E","article-title":"Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome","volume":"516","author":"Flament","year":"1990","journal-title":"Brain Res."},{"key":"10.1053\/j.sult.2020.08.011_bib0112","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bpa.12182","article-title":"Regional multiple pathology scores are associated with cognitive decline in lewy body dementias","volume":"25","author":"Howlett","year":"2015","journal-title":"Brain Pathol"},{"key":"10.1053\/j.sult.2020.08.011_bib0113","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-170390","article-title":"PET imaging of tau pathology and relationship to amyloid, longitudinal MRI, and cognitive change in down syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)","volume":"60","author":"Rafii","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1053\/j.sult.2020.08.011_bib0114","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mds.27252","article-title":"Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases","volume":"33","author":"Lee","year":"2018","journal-title":"Move Disord"},{"key":"10.1053\/j.sult.2020.08.011_bib0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaneurol.2017.3713","article-title":"Associations between tau, beta-Amyloid, and cognition in Parkinson disease","volume":"75","author":"Winer","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0116","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ana.24825","article-title":"AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies","volume":"81","author":"Kantarci","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0117","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","article-title":"Tau positron emission tomographic imaging in the lewy body diseases","volume":"73","author":"Gomperts","year":"2016","journal-title":"JAMA Neurol"},{"issue":"Pt 7","key":"10.1053\/j.sult.2020.08.011_bib0118","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/brain\/aww098","article-title":"In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET","volume":"139","author":"Hansen","year":"2016","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0119","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1038\/s41598-018-23041-x","article-title":"(18)F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies","volume":"8","author":"Smith","year":"2018","journal-title":"Sci Rep"},{"key":"10.1053\/j.sult.2020.08.011_bib0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.21192","article-title":"Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease","volume":"62","author":"Goris","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1053\/j.sult.2020.08.011_bib0121","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000065889.42856.F2","article-title":"Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies","volume":"60","author":"Merdes","year":"2003","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0122","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between Abeta, tau, and alpha-synuclein: Acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J Neurosci"},{"key":"10.1053\/j.sult.2020.08.011_bib0123","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cell.2013.05.057","article-title":"Distinct alpha-synuclein strains differentially promote tau inclusions in neurons","volume":"154","author":"Guo","year":"2013","journal-title":"Cell"},{"key":"10.1053\/j.sult.2020.08.011_bib0124","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archneur.56.2.203","article-title":"Neurofibrillary pathology in Alzheimer disease with Lewy bodies: two subgroups","volume":"56","author":"Gearing","year":"1999","journal-title":"Arch Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0125","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of tau deposition in the aging human brain","volume":"89","author":"Scholl","year":"2016","journal-title":"Neuron"},{"key":"10.1053\/j.sult.2020.08.011_bib0126","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1212\/WNL.0000000000006075","article-title":"Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease","volume":"91","author":"Aschenbrenner","year":"2018","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0127","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/brain\/awz025","article-title":"Entorhinal cortex tau, amyloid-beta, cortical thickness and memory performance in non-demented subjects","volume":"142","author":"Knopman","year":"2019","journal-title":"Brain"},{"key":"10.1053\/j.sult.2020.08.011_bib0128","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1212\/WNL.0000000000007728","article-title":"Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults","volume":"93","author":"Lowe","year":"2019","journal-title":"Neurology"},{"key":"10.1053\/j.sult.2020.08.011_bib0129","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.25395","article-title":"The impact of amyloid-beta and tau on prospective cognitive decline in older individuals","volume":"85","author":"Sperling","year":"2019","journal-title":"Ann Neurol"}],"container-title":["Seminars in Ultrasound, CT and MRI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887217120300949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887217120300949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:24:45Z","timestamp":1760135085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887217120300949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0887217120300949"],"URL":"https:\/\/doi.org\/10.1053\/j.sult.2020.08.011","relation":{},"ISSN":["0887-2171"],"issn-type":[{"value":"0887-2171","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Ultrasound, CT and MRI","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.sult.2020.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}